Sector
PharmaceuticalsOpen
₹32.55Prev. Close
₹31Turnover(Lac.)
₹0.23Day's High
₹32.55Day's Low
₹3152 Week's High
₹52.2752 Week's Low
₹25.02Book Value
₹-4.77Face Value
₹10Mkt Cap (₹ Cr.)
114.43P/E
0EPS
0Divi. Yield
023 May 2024
12:00 AM
Board Meeting
Agenda : Audited Result
8 Apr 2024
12:00 AM
EGM
4 Sep 2023
12:00 AM
AGM
Announcement Date: 04 Sep, 2023
| Y/e 31 Mar( In .Cr) | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|
Equity Capital | 14.2 | 14.2 | 10.2 | 10.2 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | -60.4 | -48.83 | -48.22 | -51.15 |
Net Worth | -46.2 | -34.63 | -38.02 | -40.95 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2020 | Mar-2019 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 13.71 | 20.5 | 12.86 | 8.15 |
yoy growth (%) | -33.11 | 59.34 | 57.82 | -34.37 |
Raw materials | -15.58 | -16.07 | -9.93 | -5.63 |
As % of sales | 113.6 | 78.4 | 77.17 | 69.1 |
Employee costs | -2.49 | -3.2 | -3.35 | -3.31 |
| Y/e 31 Mar( In .Cr) | Mar-2020 | Mar-2019 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | -9.92 | -3.49 | -4.47 | -5.72 |
Depreciation | -0.99 | -1.01 | -0.94 | -0.9 |
Tax paid | 0.15 | 0.23 | -0.04 | -0.08 |
Working capital | -1 | 5.04 | -2.12 | 3.97 |
Other operating items |
| Y/e 31 Mar | Mar-2020 | Mar-2019 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -33.11 | 59.34 | 57.82 | -34.37 |
Op profit growth | 285.21 | -48.9 | -17.46 | 16.26 |
EBIT growth | 221.53 | -23.19 | -30.22 | 2.73 |
Net profit growth | 77.87 | -28.13 | -22.05 | 5.62 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,587.9 | 124.83 | 3,80,990.4 | 867.6 | 0.85 | 5,536.99 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 4,534.75 | 76.42 | 1,20,383.36 | 531 | 0.66 | 2,259 | 507.93 |
Cipla Ltd CIPLA | 1,489.7 | 32.38 | 1,20,295.96 | 1,038.4 | 0.57 | 3,444.92 | 346.41 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,154.4 | 33.79 | 1,16,159.65 | 1,405.2 | 0.26 | 3,172.6 | 156.19 |
Dr Reddys Laboratories Ltd DRREDDY | 6,769.25 | 26.36 | 1,12,931.2 | 1,034.8 | 0.59 | 5,081.8 | 1,458.96 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Managing Director
Sai Sudhakar Vankineni
Independent Director
D Vidya Sagar
Director (Technical)
Muralidhar R
Independent Director
Sangari Kondal Reddy
Independent Director
Padmaja Surapureddy
Executive Director
Kanuganti Raghavender Rao
Additional Director
Sravani Reddy Gantla
Additional Director
Bharath Reddy Guntuku
Company Sec. & Compli. Officer
Dolly Mandhan
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Oxygenta Pharmaceutical Ltd
Summary
Oxygenta Pharmaceutical Limited (Formerly known S S Organics Ltd) was incorporated as Private Limited Company in year 1990 and converted into a Limited Company in 1993, with the objective of carrying on the business of manufacturing all classes and kinds of Drugs including Pharmaceutical preparation, and Organic Fine Chemicals. Later, the Company changed its name from S.S. Organics Ltd. to Oxygenta Pharmaceutical Limited in 2021-22.The Company is strong in manufacturing of anti ulcerative and anti bacterial drugs. The Company is doing contract manufacturing work for APL and also having its own production. The Company is engaged in manufacture of bulk drugs. It manufactures a wide range of new generation quinolones, antiasthmatic, antiulcerant, and anti-inflammatory drugs. The Company has plant located at Medak in Andhra Pradesh. The Company has been doing contract manufacturing work with APL for manufacturing of Cirprofloxacin HCL from Q-Acid and has been manufacturing Pantaprozole Sodium and Gabapentine for own production. To minimize the working capital requirement and to have consistent income, it is necessary to continue contract manufacturing work till the Company gets working capital limits from any Bank. This contract manufacturing helps it to meet major operational expenses of the Company. Since the Company started commercial production in July, 2015 after fire accident, it is in the process of stabilizing the manufacturing and marketing.
Read More
What is the Oxygenta Pharmaceutical Ltd share price today?
The Oxygenta Pharmaceutical Ltd shares price on BOMBAY STOCK EXCHANGE (BSE) is Rs.₹32.25 today.
What is the Market Cap of Oxygenta Pharmaceutical Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Oxygenta Pharmaceutical Ltd is ₹114.43 Cr. as of 23 Jul ‘24
What is the PE and PB ratio of Oxygenta Pharmaceutical Ltd?
The PE and PB ratios of Oxygenta Pharmaceutical Ltd is 0 and -6.50 as of 23 Jul ‘24
What is the 52 Week High and Low of Oxygenta Pharmaceutical Ltd?
The 52-week high/low is the highest and lowest price at which a Oxygenta Pharmaceutical Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Oxygenta Pharmaceutical Ltd is ₹25.02 and ₹52.27 as of 23 Jul ‘24
What is the CAGR of Oxygenta Pharmaceutical Ltd?
Oxygenta Pharmaceutical Ltd's CAGR for 5 Years at 33.14%, 3 Years at 43.28%, 1 Year at -20.59%, 6 Month at -7.13%, 3 Month at -21.26% and 1 Month at -13.86%.
What is the shareholding pattern of Oxygenta Pharmaceutical Ltd?
The shareholding pattern of Oxygenta Pharmaceutical Ltd is as follows:
Promoters - 33.69 %
Institutions - 0.03 %
Public - 66.29 %
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
